Page last updated: 2024-11-04

rolipram and Retinitis

rolipram has been researched along with Retinitis in 1 studies

Retinitis: Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis).

Research Excerpts

ExcerptRelevanceReference
"Rolipram treatment from days -1 to 7 after immunization (afferent phase) was not protective, but severity of EAU was reduced to 50% by treatment from days 8 to 16 after immunization or when EAU was induced by adoptive transfer (efferent phase)."1.30Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. ( Caspi, RR; Chan, CC; Rizzo, LV; Silver, PB; Strassmann, G; Wiggert, B; Xu, H, 1999)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Xu, H1
Strassmann, G1
Chan, CC1
Rizzo, LV1
Silver, PB1
Wiggert, B1
Caspi, RR1

Other Studies

1 other study available for rolipram and Retinitis

ArticleYear
Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Investigative ophthalmology & visual science, 1999, Volume: 40, Issue:5

    Topics: Adoptive Transfer; Animals; Autoimmune Diseases; DNA Primers; Dose-Response Relationship, Drug; Eye

1999